Filing Flows › NovoCure (NVCR) › Q2 2026 › vs Q2 2025
NovoCure (NVCR) Q2 2026 vs Q2 2025 (year over year)
NovoCure's revenue rose $24.8M (+16%) from $159M in Q2 2025 to $184M in Q2 2026.
NovoCure, Q2 2026: revenue $184M (+16% year over year), operating margin -5.8%, net loss $15.7M, operating cash flow $8.1M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 0.7% | -13.5% | +14.2 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $184M | $159M | $24.8M | +16% |
| Net loss | $15.7M | $40.1M | −$24.5M | -61% |
| Costs & expenses | $199M | $203M | −$4.2M | -2% |
| Operating costs | $194M | $198M | −$4.2M | -2% |
| Interest & other, net | $1.9M | −$4.5M | $6.4M | — |
| Income tax | $3.2M | $5.2M | −$2.0M | -38% |
| Cost of revenue | $41.1M | $41.5M | −$366K | -0.9% |
| Research & development | $51.4M | $55.8M | −$4.4M | -8% |
| Sales & marketing | $61.7M | $57.1M | $4.6M | +8% |
| General & admin | $39.9M | $44.0M | −$4.0M | -9% |
| Operating cash sources | $23.8M | $24.2M | −$413K | -2% |
| Depreciation & amortization | $4.3M | $3.4M | $863K | +25% |
| Share-based compensation | $17.0M | $26.1M | −$9.1M | -35% |
| Working capital & other | $2.5M | −$5.4M | $7.9M | — |
| Net loss absorbed | $15.7M | $40.1M | −$24.5M | -61% |
| Operating cash flow | $8.1M | −$15.9M | $24.1M | — |
| Free cash flow (OCF − capex) | $1.2M | −$21.4M | $22.6M | — |
| Capital expenditures | $6.9M | $5.5M | $1.4M | +26% |
Questions
How much did NovoCure's revenue grow year over year in Q2 2026?
NovoCure's revenue rose $24.8M (+16%) from $159M in Q2 2025 to $184M in Q2 2026.